Compare Biocon Ltd with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs GLENMARK PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON GLENMARK PHARMA BIOCON /
GLENMARK PHARMA
 
P/E (TTM) x 17.0 12.5 135.5% View Chart
P/BV x 2.6 1.8 146.7% View Chart
Dividend Yield % 0.4 0.5 81.5%  

Financials

 BIOCON    GLENMARK PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
GLENMARK PHARMA
Mar-19
BIOCON /
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,188712 166.9%   
Low Rs305484 63.1%   
Sales per share (Unadj.) Rs68.7349.6 19.7%  
Earnings per share (Unadj.) Rs7.632.8 23.0%  
Cash flow per share (Unadj.) Rs14.044.3 31.5%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.10.3 40.0%  
Book value per share (Unadj.) Rs86.3198.6 43.5%  
Shares outstanding (eoy) m600.00282.17 212.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.91.7 635.5%   
Avg P/E ratio x98.918.2 542.3%  
P/CF ratio (eoy) x53.413.5 396.4%  
Price / Book Value ratio x8.63.0 287.4%  
Dividend payout %13.26.1 217.0%   
Avg Mkt Cap Rs m447,900168,625 265.6%   
No. of employees `0006.112.0 51.1%   
Total wages/salary Rs m9,31120,561 45.3%   
Avg. sales/employee Rs Th6,705.88,196.0 81.8%   
Avg. wages/employee Rs Th1,514.21,708.1 88.6%   
Avg. net profit/employee Rs Th736.9768.5 95.9%   
INCOME DATA
Net Sales Rs m41,23498,655 41.8%  
Other income Rs m2,0622,081 99.1%   
Total revenues Rs m43,296100,736 43.0%   
Gross profit Rs m8,29115,858 52.3%  
Depreciation Rs m3,8513,259 118.2%   
Interest Rs m6153,346 18.4%   
Profit before tax Rs m5,88711,335 51.9%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m1,5693,756 41.8%   
Profit after tax Rs m4,5319,250 49.0%  
Gross profit margin %20.116.1 125.1%  
Effective tax rate %26.733.1 80.4%   
Net profit margin %11.09.4 117.2%  
BALANCE SHEET DATA
Current assets Rs m41,48666,968 61.9%   
Current liabilities Rs m21,41340,211 53.3%   
Net working cap to sales %48.727.1 179.5%  
Current ratio x1.91.7 116.3%  
Inventory Days Days6483 76.8%  
Debtors Days Days9481 116.0%  
Net fixed assets Rs m50,66133,322 152.0%   
Share capital Rs m3,000282 1,063.1%   
"Free" reserves Rs m48,80855,770 87.5%   
Net worth Rs m51,80856,052 92.4%   
Long term debt Rs m17,89835,738 50.1%   
Total assets Rs m99,897132,888 75.2%  
Interest coverage x10.64.4 241.0%   
Debt to equity ratio x0.30.6 54.2%  
Sales to assets ratio x0.40.7 55.6%   
Return on assets %5.29.5 54.3%  
Return on equity %8.716.5 53.0%  
Return on capital %9.617.8 54.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05862,998 19.1%   
Fx outflow Rs m7,34822,859 32.1%   
Net fx Rs m4,71040,140 11.7%   
CASH FLOW
From Operations Rs m6,62113,242 50.0%  
From Investments Rs m-6,840-6,990 97.9%  
From Financial Activity Rs m-2,397-7,387 32.4%  
Net Cashflow Rs m-2,612-2,971 87.9%  

Share Holding

Indian Promoters % 40.4 48.3 83.6%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 6.9 121.7%  
FIIs % 10.7 34.4 31.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 56,727 193.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 642 Points; Automobile and Realty Stocks Plunge(Closing)

Indian share markets fell sharply today amid fears of rising crude oil prices and weakness in the rupee rattled investor sentiment.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Sep 17, 2019 03:35 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS